Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.48

+0.1%

Dec 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (8)	7/7/1998 8:38:00 AM
From: Harold Engstrom	Read Replies (1) of 1475

Rick, thanks for your posts. How do we evaluate anti-CD2? How do you think it compares to anti-CD40L - the same indications or some overlapping indications? In transplantation indications, there will be competing products from Genetics Institute and Biogen and maybe Idec. These companies can make and market products and bring them successfully through the pipeline - do you think Biotransplant can do the same thing well? "MEDI has initiated clincals for psoriasis, kidney transplantation, and GvHD." Those are some pretty good indications. How far through trials are they? I'll do some research and see what I can come up with. Have no feeling for the company, so can you give me your impression of management and their committment and ability to execute and focus? Thanks, Harold

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next